OPRX

In a report released on November 9, Sean Dodge from RBC Capital maintained a Buy rating on OptimizeRx (OPRX - Research Report), with a price target of $22.00. The company's shares closed yesterday at $20.36.Dodge covers the Technology sector, focusing on stocks such as Allscripts, OptimizeRx, and NextGen Healthcare. According to TipRanks, Dodge has an average return of -6.2% and a 42.68% success rate on recommended stocks. OptimizeRx has an analyst consensus of Strong Buy, with a price target consensus of $27.00, a 32.61% upside from current levels. In a report released on November 9, B.Riley Financial also maintained a Buy rating on the stock with a $37.00 price target.
https://www.tipranks.com/news/blurbs/optimizerx-oprx-receives-a-buy-from-rbc-capital?utm_source=advfn.com&utm_medium=referral